North American cannabis investment firm Ela Capital has made its first foray into Australia, taking a nearly 9% stake in ASX-listed healthcare technology company Lifespot Health.

The move comes after a rights issue shortfall saw Ela snap up 11,329,573 Lifespot shares (around 8.6% of the company) at an issue price of seven cents, raising $793,070.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Ela is an investment and advisory firm that provides capital and services to companies in the cannabis medical devices and life science industries, with more than 10 holdings globally.

Ela’s involvement will be both financial and advisory, offering opportunities for Lifespot to enter lucrative markets in North America and Europe.

Lifespot Health CEO Matthew Golden: Australia’s medical market makes it attractive to US investment funds.

Lifespot CEO Matthew Golden told Cannabiz the move is a sign of increasing interest in Australia from North America.

He said: “The American market is starting to look at what other markets can offer and Australia is different because it’s a medical market.”

Golden said despite several US states liberalising laws around recreational use, most will focus on medicinal cannabis going forward.

He said while younger, mostly male, users in the US are looking to get high, “the larger portion of the population are more mature, medically focused patients using cannabis to treat a condition. For them, getting high is a negative and they are willing to spend more money for a quality product.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...